Clinical Trials · NCT05296733
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 82
- Start date
- Apr 2022
- Locations
- 13 sites, 6 countries
- Primary endpoint
- Part A: Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)